Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

EP: 1.Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

EP: 2.Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

EP: 3.Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

Now Viewing

EP: 4.Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

EP: 5.Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

EP: 6.Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer

EP: 7.Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

EP: 8.Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

EP: 9.Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

EP: 10.ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

EP: 11.Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

EP: 12.Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

Video content above is prompted by the following:

• For a patient whose cancer has progressed, do you obtain a new biopsy or go back to the original sample? Why?
• What biomarkers do you test for in advanced-stage breast cancer and when? Is there a need for NGS testing before first-line metastatic disease? (eg, BRCA, PIK3CA, PD-L1, NTRK, MSI-H/dMMR, TMB-H)